Avanos (AVNS) Director Lisa Egbuonu‑Davis Sells 25,814 Shares

What Happened

• Lisa Egbuonu‑Davis, a director of Avanos Medical, disposed of a total of 25,814 economic interests in Avanos on July 27, 2026, in connection with the company’s merger. The transactions consisted of 13,811 common shares cashed out at $25.00 each ($345,275) and 12,003 cash‑settled restricted share units (RSUs) converted to $25.00 per‑unit ($300,075). Total cash received was $645,350.
• These were dispositions to the issuer under the Merger Agreement (not open‑market sales), so proceeds reflect the merger consideration rather than a market sale.

Key Details

• Transaction date: July 27, 2026; Price: $25.00 per share/unit.
• Amounts: 13,811 shares ($345,275) + 12,003 RSUs/cash‑settled units ($300,075) = 25,814 units, $645,350 total.
• Shares/units after transaction: not specified in the Form 4 filing.
• Footnotes: Merger Agreement converted each outstanding share to $25.00 cash (F1). The 12,003 units were RSUs issued May 8, 2026 that were cash‑settled and canceled at the Effective Time of the Merger, with cash paid equal to $25.00 × units (less applicable tax withholdings) (F2, F3).
• Filing timeliness: Report filed July 28, 2026 for a July 27, 2026 transaction — filed within the normal reporting window (not indicated as late).

Context

• These disposals were driven by the company’s merger (automatic conversion/cash‑out) rather than a market sale initiated by the director; such transactions reflect deal consideration, not an independent trading decision.
• The RSU conversion was a cash settlement, so no new shares were issued to the director.